#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	18536	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2696	848.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1752	1752	C	1146	C,A	1145,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31238	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4134	943.2	0	.	n	.	0	T695C	SNP	695	695	T	1347	1347	C	1077	C,T,G	1075,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31238	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4134	943.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1989	1989	A	1318	A,G	1316,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31238	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4134	943.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2623	2623	C	1159	C,T,A	1155,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31238	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4134	943.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2697	2697	A	1032	A	1031	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31238	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4134	943.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3249	3249	C	1167	C	1167	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	2328	folP	855	855	100.0	folP.l15.c30.ctg.1	2262	128.4	1	SNP	p	R229S	0	.	.	685	687	CGC	1396	1398	CGC	195;196;196	C;G;C	195;196;196	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5944	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3913	189.5	1	SNP	p	S91F	0	.	.	271	273	TCC	821	823	TCC	228;231;229	T,C;C;C,A	227,1;231;228,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5944	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3913	189.5	1	SNP	p	D95G	0	.	.	283	285	GAC	833	835	GAC	237;234;236	G,C;A;C,A	236,1;234;235,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5944	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3913	189.5	1	SNP	p	D95N	0	.	.	283	285	GAC	833	835	GAC	237;234;236	G,C;A;C,A	236,1;234;235,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2370	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1762	167.8	1	SNP	p	G45D	1	.	.	133	135	GAC	718	720	GAC	282;285;282	G;A;C	282;285;282	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1348	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1450	115.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	5930	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3478	212.7	1	SNP	p	D86N	0	.	.	256	258	GAC	795	797	GAC	234;234;236	G;A;C	234;234;236	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	5930	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3478	212.7	1	SNP	p	S88P	0	.	.	262	264	TCC	801	803	TCC	236;236;235	T;C;C	236;236;235	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4848	parE	1986	1986	100.0	parE.l15.c17.ctg.1	3252	186.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1882	1884	GGC	252;252;253	G;G;C,T,G	252;252;250,2,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1540	1542	GCA	306;306;306	G;C;A	306;306;306	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1543	1545	ATC	307;308;310	A;T,G;C	307;307,1;310	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1555	1557	GTG	310;313;310	G;T,G;G,A	310;312,1;309,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1555	1557	GTG	310;313;310	G;T,G;G,A	310;312,1;309,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2059	2061	ACC	257;258;255	A;C;C	257;258;255	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2113	2115	GCG	263;261;263	G,A;C;G	262,1;261;263	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2113	2115	GCG	263;261;263	G,A;C;G	262,1;261;263	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2236	2238	GGC	267;264;264	G,A,C;G,T;C	265,1,1;263,1;264	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2245	2247	GGC	276;279;277	G,C;G;C,G	274,2;279;276,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4910	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2962	207.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2263	2265	CTG	288;288;287	C;T;G	288;288;287	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6722	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3644	230.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1830	1832	CCG	265;265;267	C;C,T;G,A	265;264,1;266,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2253	151.9	0	.	p	.	0	S22G	NONSYN	64	66	AGC	639	641	GGC	194;197;197	G;G;C	194;197;197	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2253	151.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	821	821	C	209	C	209	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	778	780	AAG	336;334;340	A,T;A;G	335,1;334;340	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	847	849	CAA	343;346;349	C;A;A	342;346;349	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1054	1056	GAT	337;334;334	G,A;A,G,T,C;T	336,1;331,1,1,1;334	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1057	1059	GAT	332;332;330	G;A;T	332;332;330	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	Q214H	NONSYN	640	642	CAA	1060	1062	CAT	328;327;327	C;A,G,T;T	328;325,1,1;327	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	V215T	NONSYN	643	645	GTT	1063	1065	ACT	330;327;331	A;C;T	330;327;331	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1072	1074	ATG	331;333;333	A;T,A;G	331;332,1;333	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1189	1191	ACG	326;323;323	A;C;G,C	326;323;322,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1195	1197	GTT	323;317;318	G;T;T	323;317;318	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1309	1311	AAC	324;324;323	A;A;C	324;324;323	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	1	SNP	p	D121N	0	.	.	361	363	GAC	781	783	GAC	340;342;345	G;A;C	340;342;345	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3988	porB1b	1047	1047	98.66	porB1b.l6.c30.ctg.1	1841	265.7	1	SNP	p	A121D	1	.	.	361	363	GAC	781	783	GAC	340;342;345	G;A;C	340;342;345	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	13208	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5581	295.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	2008	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1389	179.5	1	SNP	p	V57M	1	.	.	169	171	ATG	720	722	ATG	365;368;367	A,G;T;G,T	364,1;368;366,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
